Business
Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company's Scientific Advisory Board (SAB).\"We are very pleased that Stacey has joined our SAB,\" said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer. \"Being a cancer survivor herself, Stacey is a passionate advocate for patient engagement and treatment guidelines that are inclusive of shared decision-making among patients, providers, payers, and regulators. She has published extensively on patient needs and inclusion of patient-reported outcomes in clinical trials, which is well aligned with the design and conduct of our ongoing phase 3 OnTarget clinical trial of crofelemer for the prophylaxis of diarrhea in adult solid tumor patients receiving targeted therapy with or without standard chemotherapy.\"\"My focus as a patient advocate is on the quality of life of people undergoing treatment for cancer. Targeted therapies have transformed the cancer treatment ecosystem, but those additional months and years of survival often come with severe side effects,\" said Ms. Tinianov. \"With patient enrollment now complete for the Company's pivotal OnTarget phase 3 clinical trial of crofelemer, I'm excited to join the Company's SAB and absolutely thrilled to support Jaguar's mission to address the highly neglected comorbidity of cancer treatment-related diarrhea (CTD). Comfort and dignity are critical components of cancer care. CTD impacts the comfort and dignity of those on targeted cancer therapies as well as their ability to adhere to their targeted cancer therapy.\"\"Stacey shares our deep passion for empowering patients with a voice in their treatment options,\" said Lisa Conte, Jaguar's founder, president, and chief executive officer. \"She excels at building bridges between patient communities and oncology focused organizations as a patient and community engagement consultant, and we're thrilled to have Stacey join our SAB and support us in our initiatives for ensuring that crofelemer reaches oncology patients following the approval of our drug. Supportive care is cancer care, and we look forward to having her augment this very important focus at Jaguar.\"Ms. Tinianov is Vic...